Affiliate Disclaimer
Some links in this article are affiliate links. We may earn a small commission if you make a purchase through these links, at no extra cost to you. We only recommend products we find useful to our readers
(IBD) Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, affects about 10 million people worldwide.
Crohn’s disease and ulcerative colitis are the two primary forms of Inflammatory bowel disease IBD, which does not currently have a cure. Symptoms can be reduced with medication, surgery, and by your lifestyle modifications.
Eli Lilly and Company (NYSE: LLY) reported that Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist, has been approved by U.S. Food and Drug Administration (FDA) to treat adults for ulcerative colitis (UC) from moderate to severe conditions.
The drug’s manufacturer recently made public the results of two recent studies on the long-term safety and effectiveness of lebrikizumab for Crohn’s disease and ulcerative colitis.
Bruce Sands, MD, MS, senior author of the clinical trial report published in New England Journal of Medicine (NEJM), stated, “Its performance in both the induction and the maintenance phases of the clinical trials is awe-inspiring.”
According to NEJM, Mirikizumab showed remarkable outcomes in the induction and maintenance arms of phase 3 randomized, double-blind, placebo-controlled trials in individuals with moderately to severely active ulcerative colitis.
Researchers looked at the long-term effects of study participants treated with mirikizumab during the original LUCENT clinical trial program during the LUCENT-3 trial, whose findings were recently presented at the 2024 American College of Gastroenterology (ACG) Annual Meeting and published in the journal Inflammatory Bowel Diseases.
According to the study’s data, 87% of participants experienced clinical remission based on Crohn’s Disease Activity Index (CDAI), and 96% of the participants experienced a clinical response as measured by CDAI. Participants who received mirikizumab maintained high endoscopic and clinical remission rates for up to five years.
As a professor of pediatrics and medicine at Icahn Mount Sinai and a co-director of Susan and the Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Dr. Marla C. Dubinsky is also a co-author of the published phase 3 clinical trials. She said, “The Lucent program was the first clinical trial program that addressed bowel urgency in a meaningful way.”
